Cheung Darin, Hassan Mohammad Ali, Huynh Tri, Feng Xiaodong, Wang Hongbin
College of Medicine.
Department of Pharmaceutical and Biomedical Sciences College of Pharmacy, California Northstate University, 9700 West Taron Drive, Elk Grove, CA 95757, USA.
Hum Immunol. 2025 Jan;86(1):111226. doi: 10.1016/j.humimm.2024.111226. Epub 2024 Dec 27.
Complement C4 is a key component in the activation of classical and lectin complement pathways, which are observed in both animal tumor models and cancer patients. While its role in autoimmune disorders has been extensively studied, the functions of complement C4 and its activation in cancer have received inadequate consideration. Recent studies have detected C4 activation in animal tumor models and cancer patients, with its fragment C4d found in cancer tissues and lymph nodes. Elevated C4d levels could be a useful biomarker for detecting various cancers. This review aims to summarize recent developments on the role of complement C4 activation in promoting an immunosuppressive tumor microenvironment, thereby supporting tumor progression and metastasis; C4d as a biomarker; and its potential as a target for cancer immunotherapy. We also conduct a critical evaluation of methods used to measure complement C4 and its activation products, highlighting possible pitfalls and areas for improvement in existing research.
补体C4是经典和凝集素补体途径激活的关键成分,在动物肿瘤模型和癌症患者中均有观察到。虽然其在自身免疫性疾病中的作用已得到广泛研究,但补体C4及其在癌症中的激活功能却未得到充分考虑。最近的研究在动物肿瘤模型和癌症患者中检测到了C4激活,在癌组织和淋巴结中发现了其片段C4d。C4d水平升高可能是检测各种癌症的有用生物标志物。本综述旨在总结补体C4激活在促进免疫抑制性肿瘤微环境从而支持肿瘤进展和转移方面作用的最新进展;C4d作为生物标志物;以及其作为癌症免疫治疗靶点的潜力。我们还对用于测量补体C4及其激活产物的方法进行了批判性评估,强调了现有研究中可能存在的陷阱和改进领域。